Icosavax to Participate in the Cantor Fitzgerald Global Healthcare Conference 2023
Icosavax to Participate in the Cantor Fitzgerald Global Healthcare Conference 2023
About IcosavaxSEATTLE, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today announced that the company will participate in the Cantor Fitzgerald Global Healthcare Conference 2023, taking place from September 26-28, 2023 in New York City.
西雅圖，9月2023年10月19日(環球網)--生物製藥公司ICosavax，Inc.(納斯達克股票代碼：ICVX)今天宣佈，該公司將參加2023年9月26日至28日在紐約市舉行的坎託·菲茨傑拉德全球醫療大會。該公司利用其創新的病毒樣顆粒(VLP)平臺技術開發針對傳染病的疫苗，最初專注於危及生命的呼吸系統疾病，並著眼於為老年人創造泛呼吸道疫苗。
Cantor Fitzgerald Global Healthcare Conference 2023
康託·菲茨傑拉德2023年全球醫療會議
- Adam Simpson, Chief Executive Officer of Icosavax, will participate in a fireside chat in New York City on Tuesday, September 26 at 8:45 am ET in Track 3
- ICosavax首席執行官亞當·辛普森將於美國東部時間9月26日星期二上午8：45參加紐約市3號賽道的爐邊聊天
Interested parties can register for and access the live webcast for this conference by visiting the "Events" section of the Icosavax website. The webcast replay will be available after the conclusion of the presentation.
感興趣的各方可通過訪問ICosavax網站的“活動”部分註冊並收看本次會議的現場網路直播。網路直播重播將在演講結束後播出。
About Icosavax
關於ICosavax
Icosavax is a biopharmaceutical company leveraging its innovative VLP platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision for combination and pan-respiratory vaccines. Icosavax's VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens, which it believes will induce broad, robust, and durable protection against the specific viruses targeted. Icosavax's lead program is a combination vaccine candidate targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), and its pipeline includes additional programs in influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Icosavax was formed in 2017 to advance the breakthrough VLP technology from the Institute for Protein Design at the University of Washington with the goal to discover, develop, and commercialize vaccines against infectious diseases. Icosavax is located in Seattle.
ICosavax是一家生物製藥公司，利用其創新的VLP平臺技術開發針對傳染病的疫苗，最初專注於威脅生命的呼吸道疾病，並展望組合和泛呼吸道疫苗。ICosavax的VLP平臺技術旨在實現複雜病毒抗原的多價、基於顆粒的展示，該公司相信這將對目標特定病毒提供廣泛、強大和持久的保護。ICosavax的主導計劃是針對呼吸道合胞病毒(RSV)和人類偏肺病毒(HMPV)的一種組合候選疫苗，其正在籌備中的計劃包括針對流感和嚴重急性呼吸綜合徵冠狀病毒2(SARS-CoV-2)的額外計劃。ICosavax成立於2017年，旨在推進華盛頓大學蛋白質設計研究所的突破性VLP技術，目標是發現、開發傳染疫病苗並將其商業化。Icoavax公司位於西雅圖。
For more information, visit .
有關更多資訊，請訪問。
Media Contact:
Jessica Yingling, Ph.D.,
Little Dog Communications Inc.
jessica@litldog.com
858.344.8091
媒體聯繫人：
Jessica Yingling，博士，
小狗通信公司。
郵箱：jessica@litldog.com
858.344.8091
Investor Contact:
Laurence Watts
Gilmartin Group, LLC
laurence@gilmartinir.com
619.916.7620
投資者聯繫方式：
勞倫斯·瓦茨
Gilmartin Group，LLC
郵箱：laurence@gilmartinir.com
619.916.7620
